U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07342478) titled 'Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL (Phase 3)' on Jan. 13.
Brief Summary: This is a Phase 3, randomized, open-label, multicenter study comparing rocbrutinib (LP-168) versus pirtobrutinib in adult participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received a covalent Bruton's tyrosine kinase inhibitor (cBTKi). Approximately 306 participants will be randomized 1:1 to receive rocbrutinib 200 mg orally once daily or pirtobrutinib 200 mg orally once daily, administered continuously in 28-day cycles until disease progression, unaccept...